Biofil Chemicals & Pharmaceuticals Limited Stock Price Today (NSE: BIOFILCHEM)
Fundamental Score
Biofil Chemicals & Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Biofil Chemicals & Pharmaceuticals Limited share price today is ₹33.13, down 1.55% on NSE/BSE as of 16 September 2026. Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹53.92 (Cr). The 52-week high for BIOFILCHEM share price is ₹46.34 and the 52-week low is ₹25.60. At a P/E ratio of 110.43x, BIOFILCHEM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 13.81% and a debt-to-equity ratio of 0.14.
Biofil Chemicals & Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance
Biofil Chemicals & Pharmaceuticals Limited share price chart: -3.43% return over the past month. 52-week high ₹46.34, 52-week low ₹25.60.
Biofil Chemicals & Pharmaceuticals Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹33.00 | ₹33.71 | ₹33.00 | ₹33.13 | 11.77K (Cr) | |
| ₹34.40 | ₹35.49 | ₹33.10 | ₹33.65 | 33.48K (Cr) | |
| ₹37.80 | ₹37.80 | ₹32.36 | ₹34.51 | 1.73L (Cr) | |
| ₹31.46 | ₹37.75 | ₹31.46 | ₹36.79 | 6.82L (Cr) | |
| ₹32.15 | ₹32.15 | ₹31.26 | ₹31.46 | 7.17K (Cr) | |
| ₹32.70 | ₹32.70 | ₹31.50 | ₹31.52 | 12.62K (Cr) | |
| ₹31.36 | ₹32.70 | ₹31.36 | ₹32.04 | 6.96K (Cr) | |
| ₹32.80 | ₹32.80 | ₹31.31 | ₹32.00 | 5.54K (Cr) | |
| ₹32.10 | ₹32.68 | ₹31.71 | ₹31.97 | 23.21K (Cr) | |
| ₹32.60 | ₹32.80 | ₹31.55 | ₹31.95 | 4.88K (Cr) |
Biofil Chemicals & Pharmaceuticals Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹32.90 | ₹37.80 | ₹31.26 | ₹33.13 | +0.70% | |
| ₹32.05 | ₹34.68 | ₹30.12 | ₹32.59 | +1.68% | |
| ₹35.85 | ₹35.85 | ₹31.61 | ₹31.94 | -10.91% | |
| ₹35.09 | ₹39.00 | ₹33.11 | ₹34.94 | -0.43% | |
| ₹33.10 | ₹39.99 | ₹31.10 | ₹35.09 | +6.01% | |
| ₹26.69 | ₹36.30 | ₹26.51 | ₹34.05 | +27.58% | |
| ₹30.51 | ₹32.25 | ₹25.60 | ₹25.79 | -15.47% | |
| ₹39.00 | ₹46.34 | ₹31.25 | ₹32.04 | -17.85% | |
| ₹33.92 | ₹38.40 | ₹28.50 | ₹29.26 | -13.74% | |
| ₹37.20 | ₹38.25 | ₹32.52 | ₹33.57 | -9.76% | |
| ₹39.50 | ₹40.74 | ₹35.50 | ₹37.23 | -5.75% | |
| ₹40.72 | ₹43.47 | ₹38.00 | ₹39.74 | -2.41% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Biofil Chemicals & Pharmaceuticals Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biofil Chemicals & Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOFILCHEM across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (16.77%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Revenue Growth (91.99%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Excellent EPS Growth (17.61% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (17.46% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.14)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (342.54x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
7 factors identified
Margin Pressure Concerns (3.79%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Premium Valuation Risk (P/E: 110.43x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-95.47%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Growth History (-4.50% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Negative Free Cash Flow (₹-0.87 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 0.08%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Biofil Chemicals & Pharmaceuticals Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Biofil Chemicals & Pharmaceuticals Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Biofil Chemicals & Pharmaceuticals LimitedBiofil Chemical...Selected✓ BIOFILCHEM • 524396 | 44.2/100 | ₹33.13₹33 | ₹53.92₹53.92 | 110.43Average 110.4 Average | 13.81%Average 13.81% Average | 16.77%Good 16.77% Good | 0.14Excellent 0.1 Excellent | 17.46%Excellent 17.46% Excellent | -4.50%Poor -4.50% Poor | 0.00% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9425.50₹9426 | ₹249775.75₹249775.75 | 85.52Average 85.5 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4927.00₹4927 | ₹166759.24₹166759.24 | 78.71Average 78.7 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1370.00₹1370 | ₹110675.45₹110675.45 | 32.82Average 32.8 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1925.50₹1926 | ₹104025.14₹104025.14 | 95.04Average 95.0 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1675.20₹1675 | ₹96391.01₹96391.01 | 26.17Average 26.2 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2099.90₹2100 | ₹96017.92₹96017.92 | 17.35Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1141.40₹1141 | ₹95306.90₹95306.90 | 29.50Average 29.5 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2289.10₹2289 | ₹94539.83₹94539.83 | 46.25Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price249775.75 Cr
- Torrent Pharmaceuticals Limited share price166759.24 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110675.45 Cr
Biofil Chemicals & Pharmaceuticals Limited PE Ratio History
Historical price-to-earnings ratio for BIOFILCHEM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹0.44 | ₹57.45 | 130.6x |
| FY 2023 | ₹0.34 | ₹54.15 | 159.3x |
| FY 2022 | ₹0.44 | ₹55.20 | 125.5x |
| FY 2021 | ₹0.77 | ₹62.35 | 81x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Biofil Chemicals & Pharmaceuticals Limited Quarterly Performance
Latest quarterly metrics for BIOFILCHEM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
91.99%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-95.47%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-4.50%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
17.46%
Compounded annual net profit growth over 5 years
Biofil Chemicals & Pharmaceuticals Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for BIOFILCHEM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Biofil Chemicals & Pharmaceuticals Limited Financial Statements
Annual income statement, balance sheet and cash flow for Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Biofil Chemicals & Pharmaceuticals Limited
About BIOFILCHEM (Biofil Chemicals & Pharmaceuticals Limited)
Biofil Chemicals & Pharmaceuticals Ltd is a dynamic and innovative pharmaceutical company dedicated to advancing healthcare solutions. The company operates with a commitment to qua...lity, safety, and efficacy in the development, manufacturing, and distribution of a diverse range of pharmaceutical products. Biofilchem's core focus lies in addressing unmet medical needs and improving patient outcomes through cutting-edge research and development. Their state-of-the-art manufacturing facilities adhere to stringent international quality standards, ensuring that every product meets the highest level of excellence. They are driven by a team of experienced professionals and scientists, dedicated to discovering, developing, and delivering innovative therapies that make a meaningful difference in people's lives. Biofilchem is committed to ethical business practices and environmental sustainability, reflecting their responsibility towards society. Biofilchem stands as a multifaceted pharmaceutical entity, producing both active pharmaceutical ingredients (APIs) and finished dosage forms. Their expertise extends to the intricate synthesis of essential drug components and the formulation of safe and effective medications. They have built a reputation for providing high-quality, affordable medicines across various therapeutic areas, including but not limited to anti-infectives, cardiovascular, and central nervous system treatments. Beyond in-house production, Biofilchem actively collaborates with other pharmaceutical companies, offering contract manufacturing services that leverage their advanced facilities and regulatory expertise. This collaborative approach allows them to contribute to the broader healthcare ecosystem, ensuring a reliable supply of quality medications to meet growing demands. At the heart of Biofilchem's philosophy is a patient-centric approach, driving them to constantly innovate and improve their product offerings. They strive to understand the evolving needs of healthcare providers and patients, focusing on developing user-friendly formulations and convenient dosage forms. The company invests significantly in research and development, exploring novel drug delivery systems and developing generic versions of essential medicines. This commitment to innovation ensures access to affordable healthcare for a wider population. Biofilchem's dedication to quality, innovation, and ethical practices positions them as a trusted partner in the pharmaceutical industry, contributing to a healthier future for all.
Company Details
Key Leadership
BIOFILCHEM Share Price: Frequently Asked Questions
What is the current share price of Biofil Chemicals & Pharmaceuticals Limited?
Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) trades at ₹33.13 on NSE and BSE. Market cap ₹53.92 (Cr). Educational data only.
What is the P/E ratio of Biofil Chemicals & Pharmaceuticals Limited?
Biofil Chemicals & Pharmaceuticals Limited has a P/E of 110.43x vs industry average 34.89x.
What is the Bull Run score for Biofil Chemicals & Pharmaceuticals Limited?
Biofil Chemicals & Pharmaceuticals Limited has a Bull Run score of 44.2/100 based on 25+ financial parameters.
Does Biofil Chemicals & Pharmaceuticals Limited pay dividends?
Biofil Chemicals & Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Biofil Chemicals & Pharmaceuticals Limited?
Biofil Chemicals & Pharmaceuticals Limited has ROE of 13.81%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Biofil Chemicals & Pharmaceuticals Limited?
Biofil Chemicals & Pharmaceuticals Limited has debt-to-equity of 0.14.
Is Biofil Chemicals & Pharmaceuticals Limited a good investment?
Bull Run gives Biofil Chemicals & Pharmaceuticals Limited a score of 44.2/100. This is not investment advice — consult a SEBI-registered advisor.